New York drug distributor Rochester Drug Co-Operative will stop distributing opioids. The company was also the first distributor to face felony charges for its role in the opioid crisis. The company said the “significant legal and compliance expenses” of distributing opioids was “not sustainable.” (Reuters)

SmileDirectClub has struck a deal to sell aligners to orthodontists and dentists. The direct-to-consumer company previously had an exclusive partnership with Align Technology that has now expired. (CNBC)

Eli Lilly plans to sell two more insulin products at half price. The company will sell both Humalog Junior KwikPen and Humalog Mix75/25 at half of their current list price. Last year, the company also cut the price of Humalog in half. (Reuters)

Analysts have predicted more pharma dealmaking in 2020. A report from EY said it’s “highly unlikely” M&A will be as high in 2020 as last year, but it will remain strong. The report said Johnson & Johnson, Novo Nordisk, Pfizer, AstraZeneca and Eli Lilly may land large-scale deals this year. (BioPharma Dive)

A former Insys executive was sentenced to three years in jail for a bribery scheme. Lawyers said actions by Insys executives, including bribery and kickbacks to doctors, contributed to Massachusetts’ opioid crisis. (Associated Press)